Financial Performance - Consolidated Edison reported a first quarter net income of $791 million or $2.26 per share for 2025, an increase from $720 million or $2.08 per share in the same period of 2024 [1] - Adjusted earnings for the first quarter of 2025 were $792 million or $2.26 per share, compared to $742 million or $2.15 per share in 2024 [1][6] - The company reaffirmed its forecast for adjusted earnings per share for 2025 to be in the range of $5.50 to $5.70 [2] Strategic Focus - The company is focusing on robust investments in infrastructure to enhance grid security and support the clean energy transition, with projected capital investments of nearly $72 billion over the next 10 years [2] - The CEO emphasized the importance of maintaining reliability and meeting the growing demand for energy as customers increasingly rely on electricity for heating and transportation [2] Capital Management - During the first quarter, the company issued over $1.3 billion in new common equity, which satisfies its anticipated equity needs for 2025 [2] - The adjusted earnings exclude certain impacts related to the sale of its former subsidiary, Con Edison Clean Energy Businesses, and other accounting adjustments [1][6] Company Overview - Consolidated Edison is one of the largest investor-owned energy delivery companies in the U.S., with approximately $15 billion in annual revenues for the year ended December 31, 2024, and $71 billion in assets as of March 31, 2025 [7] - The company operates through several subsidiaries, including Consolidated Edison Company of New York, Inc., which provides electric, gas, and steam services in New York City and surrounding areas [7]

Core Viewpoint - Concentra Group Holding Parent, Inc. has announced a definitive agreement to acquire Pivot Onsite Innovations, enhancing its position in the onsite healthcare market [1][2][4]. Company Summary - The acquisition of Pivot Onsite Innovations will expand Concentra's network to approximately 350 clinics across more than 40 states, significantly increasing its service capabilities in onsite healthcare [7][9]. - The deal is valued at $55 million, with funding sourced from available cash and an existing revolving credit facility, and is expected to close in the second quarter of 2025 [10]. - Concentra currently has a market capitalization of $2.6 billion and anticipates earnings growth of 7.5% over the next five years [5]. Industry Summary - The onsite healthcare market is experiencing growing demand as employers prioritize immediate and accessible care within the workplace, which supports employee wellness and occupational health programs [7][11]. - The global occupational health market is projected to grow from $5.45 billion in 2025 to $8.47 billion by 2032, reflecting a compound annual growth rate (CAGR) of 6.5% [11].

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Concentra Group (CON) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Concentra Group is one of 1003 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Concentra Group (CON) , which belongs to the Zacks Medical Services industry, could be a great candidate to consider.This provider of occupational health services has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 4.51%.For the last reported quart ...

Core Insights - The article compares Concentra Group (CON) and Medpace (MEDP) to determine which stock offers better value for investors [1] - CON has a stronger Zacks Rank of 1 (Strong Buy) compared to MEDP's 3 (Hold), indicating a more favorable earnings outlook for CON [3][7] Valuation Metrics - CON has a forward P/E ratio of 15.59, significantly lower than MEDP's forward P/E of 26.38, suggesting CON is undervalued [5] - The PEG ratio for CON is 2.09, while MEDP's PEG ratio is higher at 3.58, indicating CON's expected earnings growth is more favorable relative to its valuation [5] - CON's P/B ratio stands at 9.44, compared to MEDP's 12.21, further supporting the notion that CON is a better value option [6] Value Grades - Based on various valuation metrics, CON holds a Value grade of B, while MEDP has a Value grade of C, reinforcing CON's position as the superior value stock [6]

Group 1 - Aurora Cannabis Inc. is currently ranked 2 (Buy) in the Zacks Rank system, indicating a strong potential for outperforming the market in the next one to three months [3] - The Zacks Consensus Estimate for Aurora Cannabis Inc.'s full-year earnings has increased by 2400% over the past 90 days, reflecting a significant improvement in analyst sentiment [3] - Year-to-date, Aurora Cannabis Inc. has returned approximately 3.8%, outperforming the average return of 3.4% for the Medical sector [4] Group 2 - Aurora Cannabis Inc. belongs to the Medical - Products industry, which consists of 83 individual stocks and is currently ranked 141 in the Zacks Industry Rank [5] - The average return for stocks in the Medical - Products industry this year is 6.1%, indicating that Aurora Cannabis Inc. is slightly underperforming its industry [5] - Concentra Group, another Medical stock, has outperformed the sector with a year-to-date return of 5.1% and also holds a Zacks Rank of 2 (Buy) [4][5]

Concentra Group (CON) has been beaten down lately with too much selling pressure. While the stock has lost 8.5% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that ...

Investors with an interest in Medical Services stocks have likely encountered both Concentra Group (CON) and Medpace (MEDP) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revisi ...

Financial Data and Key Metrics Changes - Revenue for Q4 2024 was $465 million, a 5.5% increase from $440.7 million in Q4 2023 [5] - Adjusted EBITDA rose to $77.5 million, up 13.6% from $68.3 million in the same quarter last year [5] - Net income was $22.8 million, with earnings per share at $0.17, slightly better than preliminary estimates but lower than the same quarter last year due to IPO recapitalization [6] - Adjusted EBITDA margin increased from 15.5% in Q4 2023 to 16.7% in Q4 2024 [5] Business Line Data and Key Metrics Changes - Occupational Health Center segment revenue was $437 million, a 5.4% increase year-over-year [11] - Workers' compensation revenue increased by 7% to $289.1 million, representing 66% of total center operating segment revenue [11][12] - Employer services revenue increased by 1.3% to $137.2 million, with visits per day declining by 4.8% [12] - On-site revenue grew by 7% to $17.1 million, with 10 new on-site centers expected to open soon [13] Market Data and Key Metrics Changes - Total patient visits per day were 46,800, a 2.1% decline year-over-year, driven by a 4.8% decrease in employer services visits [7][8] - Revenue per visit increased by 5.8% compared to the same quarter last year, driven by both workers' compensation and employer services [9] Company Strategy and Development Direction - The company aims to improve the health of America's workforce and continues to execute on strategic initiatives, including the acquisition of Nova Medical Centers [4][19] - The Nova acquisition, valued at $265 million, is expected to enhance the company's footprint and service offerings [19] - The company plans to continue its de novo strategy, with several new centers opening in 2025 [16][17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about stabilizing hiring rates and improving employer services volumes in 2025 [8][50] - The company expects to generate approximately $2.1 billion in revenue for 2025, a 10.5% increase over 2024 [25] - Adjusted EBITDA for 2025 is projected to be between $410 million and $425 million, an 11% increase over 2024 [26] Other Important Information - The company declared a quarterly cash dividend of $0.0625 per share, payable on April 1, 2025 [15] - The net leverage ratio at the end of 2024 was 3.46x, with a target of approximately 3.0x within the next 18 to 24 months [15][23] Q&A Session Summary Question: Integration approach for Nova - Management highlighted their experience with similar integrations, emphasizing the overlapping infrastructure and support systems that will facilitate the process [33][35] Question: Deleveraging pathway post-Nova acquisition - The company plans to reduce net leverage to approximately 3.5x by the end of 2025, driven by cash flow generation and EBITDA growth [36][38] Question: Exposure to tariffs and impact on volumes - Management does not foresee significant headwinds from tariffs affecting employer clients at this time [45] Question: Economic drivers for guidance in 2025 - The guidance reflects a combination of improved employer services growth and stable trends in workers' compensation, influenced by broader economic conditions [48][50] Question: P&L considerations for Q4 performance - Management noted stable cost levels for services and G&A, with some seasonality in Q4 expenses [52][54] Question: Expected improvement in Employer Services - Management anticipates trends will improve, moving towards flat year-over-year growth and slight positive growth later in the year [60] Question: Rate updates for workers' compensation and employer services - Both categories are expected to see slightly elevated rates due to inflation, with a positive outlook for 2025 [62][64] Question: Long-term growth outlook - The company expects mid to high single-digit revenue growth driven by visit growth and rate increases, alongside M&A activities [65] Question: Development activities and new centers - The guidance includes planned openings for new centers and normal growth for on-site business, with no additional M&A included [67] Question: Government pay exposure - The company has minimal exposure to Medicare and Medicaid, with less than 1% of revenue from these sources [69]

Group 1 - Consolidated Edison, Inc. has agreed to issue 6,300,000 common shares, with Barclays acting as the underwriter [1] - The common shares are expected to be issued on March 6, 2025, subject to customary closing conditions [1] - The net proceeds from the sale will be invested in the company's subsidiaries for capital requirements and general corporate purposes [2] Group 2 - The offering is made under Con Edison's effective shelf registration statement filed with the SEC, with related documents available on the SEC's website [3] - The press release clarifies that it does not constitute an offer to sell or solicit an offer to buy the securities [4] Group 3 - Consolidated Edison, Inc. is one of the largest investor-owned energy-delivery companies in the U.S., providing a range of energy-related products and services through its subsidiaries [7] - The company's subsidiaries include Consolidated Edison Company of New York, Inc., Orange and Rockland Utilities, Inc., and Con Edison Transmission, Inc. [7]